Filing identity and reporting period
Important mismatch: The supplied filing is Frequency Therapeutics, Inc.’s Form 10-K, not a Korro Bio, Inc. filing. It covers the fiscal year ended December 31, 2021, and was signed March 15, 2022. The company reported under ticker FREQ.
Business context
Frequency was a clinical-stage regenerative medicine company developing small-molecule therapies intended to activate progenitor cells. Its lead candidate, FX-322, targeted sensorineural hearing loss (SNHL); its pipeline also included FX-345 for SNHL and preclinical MS candidate FREQ-162. The company had no approved products and no product-sale revenue.
Financial performance and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $14.1 million | $37.0 million |
| Research and development | $60.9 million | $37.4 million |
| General and administrative | $37.2 million | $27.1 million |
| Operating loss | $84.0 million | $27.6 million |
| Net loss | $84.7 million | $26.5 million |
| Net loss per share | $2.47 | $0.82 |
| Net cash used in operations | $76.1 million | $45.2 million |
Revenue was entirely associated with recognition of the $80 million Astellas upfront payment as the related development services were performed; the performance obligation was completed in June 2021. Cash, cash equivalents, and marketable securities totaled $142.4 million at year-end. Cash and cash equivalents alone were $79.6 million; ending cash, cash equivalents, and restricted cash were $81.3 million. Current assets were $134.7 million and current liabilities $11.4 million.
Term-loan debt was $15.0 million at year-end ($0.8 million current and $14.2 million non-current); the stated rate was 4.75%. The company reported $44.5 million of future minimum operating lease payments. It estimated existing cash, cash equivalents, and marketable securities would fund operations through the end of 2023, subject to assumptions and execution risks.
Material changes versus 2020
- Net loss increased to $84.7 million from $26.5 million, while revenue declined as the Astellas upfront payment was substantially recognized over the collaboration-service period.
- R&D expense rose $23.5 million, reflecting clinical work on FX-322 and increased development of FX-345 and FREQ-162, as well as higher personnel and facility costs. G&A expense rose $10.1 million.
- Operating cash use increased to $76.1 million. Investing activities used $66.1 million, mainly reflecting purchases of marketable securities; financing provided $1.4 million, versus $56.7 million in 2020, which included a private placement and term loan.
- The company began dosing the FX-322 Phase 2b trial in October 2021, introduced FX-345 and FREQ-162, and completed recognition of the Astellas upfront payment.
Outlook, risks, and unusual items
- FX-322 evidence is mixed: The Phase 2a trial found no improvement versus placebo on hearing measures; management attributed the result to potential bias and a single baseline measure, but efficacy remains unproven. Certain earlier single-dose studies reported speech-perception signals, including a Phase 1b study in which 34% of treated subjects achieved at least a 10% absolute improvement in word-recognition scores at day 90. These small or exploratory findings do not establish efficacy.
- The Phase 2b trial was designed for approximately 124 participants with noise-induced or sudden SNHL, using speech perception as its primary endpoint and a lead-in with repeated baseline testing to address variability. Management anticipated an FX-345 IND filing in the second half of 2022 and clinical-trial initiation for an MS candidate in 2023; these are forward-looking plans, not assured outcomes.
- Funding needs are ongoing. Management expected further losses and negative cash flows and noted that additional financing may be required; financing might be unavailable or dilutive. An ATM program authorized up to $125 million of gross sales, but no shares had been sold under it by year-end 2021.
- Under the Astellas agreement, potential future development milestones total up to $230 million, with up to $315 million in commercial milestones plus tiered royalties. These amounts are contingent and were not recognized as revenue. Astellas holds development and commercialization rights outside the United States.
- Key risks include clinical and regulatory failure, dependence on FX-322, trial enrollment and COVID-19 disruption, reliance on contract manufacturers and CROs, intellectual-property and licensing obligations, competition, and future capital requirements.
- The company disclosed two securities class actions alleging misleading statements about FX-322 Phase 2a disclosures and a separate Delaware stockholder lawsuit. It said it was defending the cases; possible loss could not be estimated and no accrual was recorded.
- The independent auditor issued an unqualified opinion on the financial statements. Management reported disclosure controls and internal control over financial reporting effective at year-end; the auditor was not engaged to audit internal control.
Most important facts for investors to verify
- Confirm the issuer: this filing is for Frequency Therapeutics, not Korro Bio.
- Review subsequent FX-322 Phase 2b results and whether the trial design resolved baseline and placebo concerns.
- Check actual cash burn, financing activity, and runway against management’s end-of-2023 estimate.
- Verify progress and funding implications for FX-345, FREQ-162, and Astellas milestones.
- Track developments in the disclosed litigation and any resulting financial exposure.